

Docket No. 13762 US (C38435/109729)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applio	eation of:	) `		
Scott W. VAN ARSDELL, et al.		)	Examiner:	P. Tung
Serial No.:	08/914,332	)	Art Unit: 16	
Filed:	July 14, 1997	).	•	
For:	OVERCOMING DAPA AMINO TRANSFERASE BOTTLENECKS IN	)		
	BIOTIN VITAMERS BIOSYNTHESIS	)		

New York, New York August 8, 2000

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, DC 20231

Sir:

Applicants wish to make of record the following documents (clean copies and Form PTO-1449 are enclosed).

## OTHER DOCUMENTS

- C2 Eisenberg, et al., "Biosynthesis of Biotin and Lipoic Acid," in <u>Escherichia Coli and Salmonella Typhimurium</u>, Vol. 1, F.C. Neidhardt, et al., Eds., pp. 544-550 (1987).
- Izumi, *et al.*, "7,8-Diaminopelargonic Acid Aminotransferase, an Enzyme Involved in Biotin Biosynthesis by Microorganisms," <u>Agr. Biol. Chem.</u>, 39(1), pp. 175-181 (1975).
- C4 Sakurai, et al., "Construction of a Biotin-Overproducing Strain of Serratia marcescens," Applied and Environmental Microbiology, Vol. 59, No. 9, pp. 2857-2863 (1993).

1

2-3,5,57

250795.01

Applicants request that these documents be considered by the Examiner before issuance of the next action and made of record in this file. The Examiner is also asked to initial and return a copy of the enclosed PTO-1449 form to evidence such consideration.

This Information Disclosure Statement is being filed in accordance with the following provisions:

Applicants hereby petition the Commission of Patents and Trademarks to consider this Supplemental Information Disclosure Statement.

- [x] This Information Disclosure Statement is accompanied by the \$240.00 fee set forth in 37 CFR § 1.17(p).
- [x] 37 CFR § 1.97(e)(2). Upon information and belief, no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned after making reasonable inquiry, that no item of information in this information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement.

If our check is missing or otherwise insufficient, or if a check has not been submitted but it is determined that a fee is required as set forth in 37 CFR § 1.17(p) or 1.17(i)(1).

or if any additional fees are required, please charge such fee (or credit any overpayment) to

Deposit Account No. 02-4467. A duplicate copy of this document is enclosed.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on <u>August 8</u>, 2000.

Kevin C. Hooper

Respectfully submitted,

**3**y:\_\_\_\_

Kevin C. Hooper

Registration No. 40,402

BRYAN CAVE LLP

245 Park Avenue New York, NY 10167-0034

(212) 692-1800